New York’s attorney general seeking answers from payers about hepatitis C drugs: 4 insights

New York Attorney General Eric Schneiderman questioned 16 payers about why they denied hepatitis C drugs to specific patients, according to Business Insider.

Advertisement

Here are four insights:

1. The attorney general’s office questions whether payers are limiting coverage for those patients who are very sick.

2. The office also wants to know how payers authorize the use of hepatitis C drugs.

3. The office sent subpoenas to payers including Aetna, CareConnect and EmblemHealth.

4. Because of hepatitis C’s escalated cost, payers are conflicted whether they should prioritize medication access to patients who have progressed further with the disease.

More articles on coding, billing & collections:
Oscar suffers $105M financial losses on ACA exchanges — 5 key points
Florida House approves free-market healthcare reform proposals — 8 key points
President Obama to speak in Milwaukee about ACA’s impact: 6 takeaways

Advertisement

Next Up in ASC Coding, Billing & Collections

Advertisement

Comments are closed.